-
During the year, there have been more than 200 mergers and acquisitions in the pharmaceutical industry, involving a number of Chinese medicine enterprises
Time of Update: 2022-10-12
For example, on the evening of September 25, Longshen Rongfa issued a major asset purchase plan (draft), and the company intends to acquire 70% of the equity of Puan Pharmaceutical held by the controlling shareholders Gansu Pharmaceutical Group and Gansu Nongken Group by paying cash, with a total consideration of 326 million yuan.
-
Another multinational pharmaceutical company sold its factories in China to rearrange its business in the Chinese market
Time of Update: 2022-10-12
【Pharmaceutical Network Industry Dynamics】 In recent years, multinational pharmaceutical companies are generally facing the "patent cliff" of original research drugs, and in this context, multinational pharmaceutical companies have also become very frequent in selling business in China.
-
The domestic demand for medicinal glass tubes is increasing, and the pharmaceutical glass faucet is accelerating the expansion of production
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】In recent years, with the continuous expansion of the pharmaceutical market and the stricter supervision of the industry, the quality and safety of drugs have att
-
The official disclosure period of the third quarterly report is coming! The net profit of some pharmaceutical companies increased sharply year-on-year
Time of Update: 2022-10-12
According to the statistics of the lower limit of the net profit attributable to the forecast, 63 stocks achieved a year-on-year increase in net profit, accounting for 70%.
-
The ophthalmic treatment track has begun, and domestic and foreign pharmaceutical companies are competing for layout
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】With the intensification of population aging and the increase in the use of electronic products, age-related eye diseases, metabolism-related eye diseases and fun
-
Notice of the Drug Review Center of the State Food and Drug Administration on the Issuance of the Technical Guidelines for the Research of Clinical Dependence of Drugs (Trial) (No. 35 [2022])
Time of Update: 2022-10-12
Notice of the Drug Review Center of the State Food and Drug Administration on the Issuance of the Technical Guidelines for the Research of Clinical Dependence of Drugs (Trial) (No. 35 [2022]) Release date: 20220928 Drug clinical dependence research is an important research content before the market of new drugs with potential abuse risks, and there is no specialized technical requirement for standardized management of such studies in China.
-
"Peroxin" withdrew from the Chinese market; The growth of the "troika" is weak; How does Roche continue to shine?
Time of Update: 2022-10-12
196 billion; at present, only Roche Pharmaceutical Pailuoxin and Tebao Bio Hepatitis B infectious hormone Paigebin, two polyethylene glycol interferon α-2b injections are listed, it is worth noting that before Pailokhin was Roche's champion product in China - interferon brand sales champion, and repeatedly exchanged price for volume, prompting its rapid growth in the Chinese market.
-
Announcement of the State Food and Drug Administration on the Issuance of Electronic Registration Certificates for Drugs (No. 83 of 2022)
Time of Update: 2022-10-12
Today, the State Food and Drug Administration issued an announcement on the issuance of electronic registration certificates for drugs (No. 83 of 2022), the details of which are as follows: In order
-
More than 500 kinds of Chinese medicine tablets are included in medical insurance, and the market is expected to further expand
Time of Update: 2022-10-12
According to the notice, 551 kinds of Chinese medicine tablets that meet the conditions have been officially added to the scope of medical insurance payment, and have been officially implemented in Hunan Province since October 1, with a validity period of 3 years.
-
Ashland fully upgrades Viatel™ Smart Bio absorbable materials capacity and R&D capabilities
Time of Update: 2022-10-12
com Scan the code to follow the latest developments in Ashland China Wilmington, Delaware, Aug. 30, 2022 – Ashland announces the expansion of Viatel's™ smart bioabsorbable materials production and R&D facility at the National Science Park in Maringa, Ireland.
-
The deputy general manager of "Pharmaceutical Brother" is replaced, or accelerate the promotion of research and development
Time of Update: 2022-10-12
It is understood that Tao Weikang, who left the company, has served as deputy general manager of Shanghai Hengrui Pharmaceutical Co.
It is understood that Tao Weikang, who left the company, has served as deputy general manager of Shanghai Hengrui Pharmaceutical Co.
-
Grey Pharmaceutical Commercialization Examination! After Pailokhin, how to make up for the revenue gap?
Time of Update: 2022-10-12
Karley Pharma recently announced that Graeley Biotechnology (Hangzhou) Co. , Ltd. , a wholly-owned subsidiary of the Company, and Shanghai Roche Pharmaceutical Co. , Ltd. (Roche Pharmaceutical) compl
-
These new regulations were officially implemented on October 1, which has a huge impact on drug sales!
Time of Update: 2022-10-12
From October 1, a number of new policies began to be implemented. . . 1. Beijing medical insurance reduces the burden, and more than 100 kinds of drugs are included in the reimbursement In September,
-
Assist in the special rectification of drug safety, and many places are paying close attention to the quality supervision of Chinese herbal medicines
Time of Update: 2022-10-12
Under the impetus of national policies, at present, more and more attention is paid to the quality and safety of the Chinese herbal medicine industry, and in the future, in order to promote the standardized large-scale planting of Chinese herbal medicines and improve the quality of Chinese herbal medicines, such rectification actions are expected to be normalized in various places.
-
The commercialization/R&D of innovative drugs is constantly achieving new breakthroughs, and it is recommended to pay attention to these companies
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】 Biomedical innovation is related to people's health, and the development of pharmaceutical industry is the fundamental embodiment and guarantee of the people's p
-
In order to break the competition in the same industry, this Chinese medicine tablet company has a new action!
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Chinese medicine tablets are one of the three pillars of China's traditional Chinese medicine industry, which is in the middle link of the traditional Chinese med
-
Many places are accelerating the exploration of TCM medical insurance payment reform!
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Recently, Guangxi held a performance evaluation report meeting on the reform of medical insurance payment methods for the dominant diseases of traditional Chinese
-
A number of local API companies pass Jiayin, which is related to the approval of products and the construction of production capacity
Time of Update: 2022-10-12
Hokuriku Pharmaceutical announced on the evening of September 29 that recently, the company's repaglinide API received the "Notice of Approval of Chemical API Listing Application" issued by the State Food and Drug Administration.
-
Progress in rare disease drug research in China
Time of Update: 2022-10-12
(See Figure 2 for details) Although the economic return is not the most cost-effective, the proportion of rare disease drug research and development in the world's leading pharmaceutical companies is relatively high.
-
Under the rapid growth of the big health market, pharmaceutical machinery enterprises are actively laying out
Time of Update: 2022-10-12
). In addition, as a traditional pharmaceutical equipment enterprise, Qianyan Yam Machine has also been seeking transformation since 2014, and has launched a number of mergers and acquisitions and foreign investments in the fields of genetic testing, big health management, medical devices and other fields, and has successively set up a number of subsidiaries.
